Wednesday, June 10, 2026

pharma Β· Schizophrenia Β· Alzheimer's Disease Psychosis Β· ACAD

Acadia Pharmaceuticals

Acadia Pharmaceuticals clinical programs β€” 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Indianapolis, USA HQ
17 Employees
Public company Type
ACAD Β· NYSE Ticker
Company details
Intelligence Β· Clinical Programs

Acadia Pharmaceuticals projects

1 ClinicalTrials.gov programs sponsored by Acadia Pharmaceuticals.

Acadia Pharmaceuticals has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Acadia Pharmaceuticals have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.